Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling 333,700 shares, a growth of 32.7% from the September 30th total of 251,400 shares. Based on an average daily volume of 3,570,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.5% of the shares of the stock are sold short.

Apollomics Stock Performance

NASDAQ APLM remained flat at $0.14 during mid-day trading on Friday. The company had a trading volume of 834,587 shares, compared to its average volume of 933,299. The stock’s fifty day moving average is $0.13 and its 200 day moving average is $0.23. Apollomics has a 1 year low of $0.11 and a 1 year high of $1.79.

Institutional Trading of Apollomics

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation increased its position in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 670,976 shares of the company’s stock after acquiring an additional 645,992 shares during the quarter. Apollomics makes up about 0.0% of George Kaiser Family Foundation’s portfolio, making the stock its 18th biggest holding. George Kaiser Family Foundation owned approximately 0.75% of Apollomics worth $141,000 at the end of the most recent reporting period. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.